Loading stock data…
WGS
$65.38+2.49 (+3.96%)
Market ClosedLast close May 1
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GeneDx Holdings Corp. in the Healthcare sector is trading at $65.38. The stock is currently near its 52-week low of $55.17, remaining 40.1% below its 200-day moving average. Technical signals show neutral RSI of 57 and bullish MACD crossover, explaining why WGS maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$65.38
Potential Upside
5%
Whystock Fair Value$68.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$136.11+108.2%
Range$90.00 – $177.00
Fundamentals
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also dev...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-90.99%
Volume
Today's trading volume
423,797
Recent News
Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings?
GeneDx heads into Q1 earnings results with strong exome and genome momentum, supported by expanding adoption and a growing rare-disease data advantage.
SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases
By Karen Roman SkylineDx said it can predict metastases and outperform existing staging systems for the country’s second most common type of skin cancer, Cutaneous Squamous Cell Carcinoma (CSCC). The results will be presented at the 22nd European Association of Dermato-Oncology Congress, held on April 23-25, 2026, in Prague and online. “This marks our first […]
Three Best Genomics Stocks for Your Portfolio in 2026
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.
Assessing GeneDx Holdings (WGS) Valuation After Recent Share Price Weakness And Growth Expectations
GeneDx Holdings update: what recent performance signals for investors GeneDx Holdings (WGS) has drawn attention after a difficult stretch in the stock, including negative returns over the past month, past 3 months, and year, despite positive annual revenue and net income growth. See our latest analysis for GeneDx Holdings. At a share price of $59.62, GeneDx Holdings has experienced a sharp loss of momentum, with a 30-day share price return of 23.35% and a year to date share price return of...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Three stocks that have fallen more than 23% this year were on the Ark Invest CEO's shopping radar on Tuesday.